Why the study?
Chronic heart failure in elderly patients carries high morbidity and mortality, especially with comorbidities, warranting review of biomarker-based prognostic value.
Does the combined use of NT-proBNP and sST2 improve risk stratification in elderly patients with chronic heart failure and comorbidities?
Does the combined use of NT-proBNP and sST2 improve risk stratification in elderly patients with chronic heart failure and comorbidities?
The combined use of NT-proBNP and sST2 biomarkers may improve risk stratification and help personalize therapy in elderly patients with chronic heart failure and comorbidities.
May aid risk stratification in elderly comorbid HF; leaves open prospective validation before clinical adoption.
Chronic heart failure (HF) in elderly patients is characterized by high morbidity and mortality, especially in the presence of comorbidities. The article presents a review of current data on the prognostic value of blood biomarkers — N-terminal pro-brain natriuretic peptide (NT-proBNP) and soluble ST2 receptor (sST2) in elderly comorbid patients with chronic heart failure (CHF). Based on the analysis, the rationale for the combined use of NT-proBNP and sST2 for accurate risk stratification and personalization of therapeutic approaches in elderly patients with CHF and multiple comorbidities is substantiated.
No takes yet. Share an insight, caveat, or question.
Kochetkova et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: